Short interest for BeiGene gives investors a sense of the degree to which investors are betting on the decline of BeiGene's stock. Short interest data is updated every two weeks.

BeiGene Stock (NASDAQ:BGNE), Short Interest Report

BeiGene

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

Growth,Chart.,Glowing,Rise,Up,Arrow,On,The,Top,Of

Large Cap

News

Movers

BGNE

CARR

FCNCA

LSCC

MCHP

MPWR

TSLA

Last week&#39;s top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation. 

Tracking Last Week&#39;s Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)

Asia

Markets

General

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Key Takeaways:


	Hillhouse Capital has raised its shareholding in Longi back to 5% after being investigated by the Chinese securities regulator for violating disclosure rules


Hillhouse Boosts Longi Position After Robe, As It Pivots To Global Focus

Intraday Update

CRML

FCEL

HIBB

HRTX

HSTM

MARA

MESO

RGEN

RNAC

ROKU

SMCI

SMXT

SPCE

SPOT

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday

BeiGene, Ltd. - American Depositary Shares

BeiGene Ltd

MRNA

FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12

Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $0.04 by 2103.25 percent. The company reported quarterly sales of $152.177 million which beat the analyst consensus estimate of $113.850 million by 33.67 percent. This is a 12.16 percent increase over sales of $135.680 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

TSAT

Telesat Q1 2024 GAAP EPS $(0.80) Misses $0.04 Estimate, Sales $152.177M Beat $113.850M Estimate

Mizuho analyst Vikram Malhorta maintains Essential Props Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Buy and raises the price target from $26 to $29.

Price Target

Analyst Ratings

EPRT

Mizuho Maintains Buy on Essential Props Realty, Raises Price Target to $29

Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 19.44 percent increase over losses of $(0.36) per share from the same period last year.

HUMA

Humacyte Q1 EPS $(0.29) Misses $(0.23) Estimate, Exits Quarter With Cash & Equivalents Worth $115.5M

Financial&nbsp;Outlook:
Based on information available as of May 10, 2024, for the&nbsp;second quarter&nbsp;of 2024 we expect:
<ul>
<li>Total revenue of&nbsp;$188&nbsp;to&nbsp;$189 million.</li>
<li>Adjusted EBITDA margin of&nbsp;37%&nbsp;to&nbsp;38%.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$0.38&nbsp;to&nbsp;$0.40.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>
For the full year 2024, we expect:
<ul>
<li>Total revenue of&nbsp;$760&nbsp;to&nbsp;$775 million.</li>
<li>Adjusted EBITDA margin of&nbsp;36%&nbsp;to&nbsp;38%.</li>
<li>Adjusted free cash flow margin in the range of&nbsp;19%&nbsp;to&nbsp;21%&nbsp;of revenue.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$1.60&nbsp;to&nbsp;$1.67.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>

Guidance

DOCN

DigitalOcean Holdings Expects Q2 Revenue of $188M-$189M Vs $187.09M Est, Adj EPS of $0.38-$0.40 Vs $0.39 Est

Sports

Media

INSE

Inspired Entertainment Launches NBA Re-Play Virtual Sports Product On Greece With OPAP

Needham analyst Charles Shi reiterates Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Hold.

Reiteration

ONTO

Needham Reiterates Hold on Onto Innovation

Mizuho analyst Haendel St. Juste maintains Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) with a Neutral and raises the price target from $60 to $62.

Mizuho Maintains Neutral on Agree Realty, Raises Price Target to $62

<a href="https://www.benzinga.com/topic/spot-bitcoin-etf">Bitcoin spot exchange-traded funds</a> (ETFs) saw net outflows of $11.29 million on May 9.
What Happened: The Grayscale Bitcoin Trust (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#OTC">GBTC</a>) <a href="https://sosovalue.xyz/assets/us-btc-spot">registered</a> a substantial net outflow of $43.3522 million, while the BlackRock Bitcoin Trust (NASADAQ: IBIT) experienced a net inflow of $14.1946 million. Other ETFs also saw modest inflows:
<ul>
<li>Fidelity (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>): $3 million</li>
<li>Ark (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>): $4 million</li>
<li>Bitwise (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BITB#BATS">BITB</a>): $7 million</li>
<li>Invesco (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BTCO#BATS">BTCO</a>): $2 million</li>
</ul>
Analysts from QCP Capital indicated that the market is adjusting to the anticipations of two Federal Reserve rate cuts later this year, with the first cut expected no earlier than September.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38736514/donald-trump-says-you-better-vote-for-him-if-youre-pro-crypto-but-has-he-always-been-fine-">Donald Trump Says &#8216;You Better Vote&#8217; For Him If You&#8217;re Pro-Crypto: But Has He Always Been &#8216;Fine With It&#8217;?</a>
Why It Matters: Despite the outflows, there isn't a sense of bearish panic among traders.
Instead, the market is adapting to a scenario of lower volatility, with a structurally positive outlook on Bitcoin towards the year-end. 
Additionally, the U.S. Dollar has been on the rise, driven by expectations that other central banks may delay their rate cuts until after the Federal Reserve acts.
This cautious yet optimistic market sentiment aligns with the themes poised to be discussed at the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
The conference aims to delve into the dynamics of cryptocurrency investments and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38587443/what-the-fomc-meeting-means-for-bitcoins-next-move">broader economic factors</a> influencing these digital assets.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38733156/house-challenges-sec-over-crypto-custody-rules-biden-vows-blockade">House Challenges SEC Over Crypto Custody Rules, Biden Vows Blockade</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

Invesco Galaxy Bitcoin ETF Invesco Galaxy Bitcoin ETF

BTCO

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

GBTC

IBIT

Bitcoin Spot ETFs Collect $11.29M Net Inflows On Thursday

TBRG

TruBridge Q1 2024 Adj EPS $0.19 Beats $0.15 Estimate, Sales $83.247M Beat $83.013M Estimate

Mizuho analyst Siti Panigrahi upgrades Squarespace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) from Neutral to Buy and raises the price target from $34 to $50.

Upgrades

SQSP

Mizuho Upgrades Squarespace to Buy, Raises Price Target to $50

Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.10 by 20 percent. This is a 20 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $17.200 million which missed the analyst consensus estimate of $17.375 million by 1.01 percent. This is a 16.94 percent increase over sales of $14.708 million the same period last year.

SACH

Sachem Cap Q1 2024 GAAP EPS $0.08 Misses $0.10 Estimate, Sales $17.200M Miss $17.375M Estimate

DigitalOcean Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCN#NYSE">DOCN</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.38 by 13.16 percent. The company reported quarterly sales of $184.730 million which beat the analyst consensus estimate of $182.584 million by 1.18 percent. This is a 11.87 percent increase over sales of $165.134 million the same period last year.

DigitalOcean Holdings Q1 2024 Adj EPS $0.43 Beats $0.38 Estimate, Sales $184.730M Beat $182.584M Estimate

AMC Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) reported quarterly earnings of $1.16 per share which missed the analyst consensus estimate of $1.67 by 30.54 percent. The company reported quarterly sales of $596.460 million which missed the analyst consensus estimate of $602.602 million by 1.02 percent. This is a 16.86 percent decrease over sales of $717.447 million the same period last year.

AMCX

AMC Networks Q1 2024 Adj EPS $1.16 Misses $1.67 Estimate, Sales $596.460M Miss $602.602M Estimate

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and maintains $35 price target.

Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target

Twitter cofounder <a href="https://www.benzinga.com/topic/jack-dorsey">Jack Dorsey</a> has revealed that he tried to bring on tech billionaire and now X owner, Elon Musk, on the board of the social media company twice.
What Happened: Dorsey, in a recent interview <a href="https://www.piratewires.com/p/interview-with-jack-dorsey-mike-solana">with</a> Pirate Wires, disclosed that he had attempted to bring Musk onto Twitter&#8217;s board on two occasions, but the board had turned down his requests.
Despite the rejections, Musk, who had a strong affinity for X, ended up acquiring the social media company after a series of controversial events in 2022.
Amid his attempts to bring in Musk and his eventual exit from the company he co-founded, Dorsey was put off by the entry of an activist CEO.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
&#8220;When our activist came in, I offered to step down as CEO and the board wanted to go in a different direction. I didn&#8217;t want to be on a board with an activist. I didn&#8217;t want to run a company like that. It&#8217;s just a Wall Street mess."
"So, at that point, I&#8217;m like, okay, I have to plan an exit,&#8221; Dorsey explained.
This set off a chain of events between Musk and X's management at the time for several months.
See Also: <a href="https://www.benzinga.com/news/24/05/38754725/elon-musk-going-for-youtube-billionaire-now-wants-you-to-post-your-movies-tv-shows-and-podcasts-on-x">Elon Musk Going For YouTube? Billionaire Now Wants You To Post Your Movies, TV Shows, And Podcasts On X To Monetize</a>
"I had tried to get Elon on the board for some time. He obviously loves Twitter," said Dorsey, explaining why he wanted to bring Musk on board in the first place.
"I tried to get him on the board twice before, but the board ultimately said no both times. Which also was one of the reasons I left, the second time that that happened."
Dorsey stepped down as Twitter's CEO in November 2021, weeks before Musk started scooping up shares of the company.
Why It Matters: Dorsey and Musk's friendship goes way back, and the two tech personalities also share a lot in common. After Musk left Meta Platforms Inc.'s Instagram, <a href="https://www.benzinga.com/news/23/08/33909290/jack-dorsey-takes-cue-from-musk-leaves-instagram-after-12-years-clear-eyes-meta-free-cant-lose">Dorsey followed in his footsteps</a>.
Musk also admires Dorsey and has publicly said he <a href="https://www.benzinga.com/news/22/05/27434516/elon-musk-a-fan-of-jack-dorsey-wishes-he-would-have-stayed-on-twitters-board-but-that-horse-has-alre">wanted Dorsey to remain</a> on Twitter's board.
Musk acquired Twitter in a $44 billion deal after months-long back and forth, <a href="https://www.benzinga.com/m-a/22/10/29458281/elon-musk-takes-over-twitter-whos-in-charge-whos-gone-and-what-happens-to-the-stock">closing the purchase</a> in October 2022.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next: <a href="https://www.benzinga.com/news/24/05/38725610/chatgpt-creator-sam-altman-feels-its-a-massive-massive-issue-that-we-dont-take-ais-threat-to-jobs-an?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">ChatGPT Creator Sam Altman Feels It&#8217;s A &#8216;Massive, Massive Issue&#8217; That We Don&#8217;t Take AI&#8217;s Threat To Jobs And Economy ‘Seriously Enough'</a>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photos courtesy: Wikimedia and Shutterstock

Social Media

Tech

Elon Musk Was Denied Twitter Board Seat Twice Despite Jack Dorsey's Attempts: 'One Of The Reasons I Left'

Morgan Stanley analyst Adam Jonas upgrades Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) from Equal-Weight to Overweight and raises the price target from $150 to $160.

Morgan Stanley Upgrades Lear to Overweight, Raises Price Target to $160

Needham analyst Bernie McTernan maintains Vacasa (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCSA#NASDAQ">VCSA</a>) with a Buy and lowers the price target from $10 to $8.

VCSA

Needham Maintains Buy on Vacasa, Lowers Price Target to $8

ANI continues to expect total company adjusted non-GAAP gross margin between&nbsp;62%&nbsp;and&nbsp;63%&nbsp;and the Company will continue to tax effect non-GAAP adjustments for computation of adjusted non-GAAP diluted earnings per share at a tax rate of&nbsp;26.0%.
The Company now anticipates between 19.4 million and 19.7 million shares outstanding (reflective of a full year of shares outstanding resulting from the May 2023 equity raise) for the purpose of calculating diluted EPS and now expects its U.S. GAAP effective tax rate to be between&nbsp;22.0%&nbsp;to&nbsp;25.0%&nbsp;as compared to&nbsp;20.0%&nbsp;to&nbsp;22.0%.

ANIP

ANI Pharmaceuticals Reiterates FY24 Outlook Of $520M-$542M Vs. $535.11M Estimate, Projects FY24 Adjusted EPS Of $4.26- $4.67 Vs. $4.48 Estimate

WIIM

NVTS

Navitas Semiconductor shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

EU regulators approve BeiGene's tislelizumab for lung cancer

Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (BGNE – Research Report) today and set a price target of $152.00. The company's...

BeiGene (BGNE) Receives a Hold from Bernstein

These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

AstraZeneca: Strong In A Weak Market

BeiGene, AbbVie patent spat to get trial from USPTO appeals board

BeiGene GAAP EPADS of -$2.41 beats by $0.48, revenue of $751.65M beats by $76.42M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BeiGene (NASDAQ:<a href="https://investorplace.com/stock-quotes/bgne-stock-quote/">BGNE</a>) just reported results for the first quarter of 2024.<ul><li>BeiGene reported earnings per share of -$2.41. This was above the analyst estimate for EPS of -$2.89.</li><li>The company reported revenue of $751.65 million.</li><li>This was 11.43% better than the analyst estimate for revenue of $674.53 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bgne-stock-earnings-beigene-for-q1-of-2024/">BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024

BeiGene, Ltd. (BGNE) has disclosed a new risk, in the Accounting & Financial Operations category. BeiGene, Ltd. faces new and materially updated ri...

New Risks Emerge for BeiGene: Investors Alerted to Material Updates in Financial Disclosures

Leerink Partners analyst Andrew Berens maintained a Buy rating on BeiGene (BGNE – Research Report) on May 8 and set a price target of $267.00. Andr...

Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales

Analyst Jill Wu from CMB International Securities maintained a Buy rating on BeiGene (BGNE – Research Report) and increased the price target to $26...

BeiGene's Soaring Sales and Path to Profitability Reinforce Buy Rating

ABBV

ADAP

APLM

APLMW

ASPHF

AUTL

BEIGF

BMYMP

CRTHF

DAWN

DCPH

DMPWW

DSKYF

DSNKY

GILD

GLAXF

INCY

IOVA

JBPHF

KTRA

MDNAF

MPSYF

NVCR

NVSEF

RCUS

REGN

RHHBF

RHHBY

RHHVF

SMMT

SNYNF

SPHRF

SPHRY

SRRK

TKPHF

Press Releases

BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Opinion

Thinking about trading options or stock in NVIDIA, Tesla, Oracle, Broadcom, or Beigene?

Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report

-

-

-

-

-

-

-

-

-

-

-

-

-

-

BeiGene Stock (NASDAQ:BGNE), Short Interest Report

People Also Watch